By Mark DaCosta- Amid decades of mounting concerns over antibiotic resistance and counterfeit medications, the People’s Progressive Party (PPP) government has finally turned its attention towards strengthening regulatory measures in our nation’s healthcare sector. This long overdue shift comes after prolonged advocacy from health experts, who have long highlighted the dangers posed by irresponsible antibiotic use and the proliferation of counterfeit drugs.
Health Minister Dr. Frank Anthony issued a stern warning to pharmacies found selling antibiotics without prescriptions, signalling imminent closures for violators. “It is imperative that pharmacies adhere strictly to existing laws,” Dr. Anthony emphasised. Apparently, reports of pharmacies flouting regulations have prompted this crackdown, underscoring the need for immediate corrective action to curb antimicrobial resistance (AMR).
Antimicrobial resistance poses a significant threat globally, with the World Health Organisation (WHO) estimating that it contributes to nearly seven million deaths annually. Dr. Anthony stressed that our nation has not been immune to this crisis, citing cases of multi-drug-resistant tuberculosis and other resistant infections as clear indicators of the urgent need for regulatory reform.
“Incorrect use of antibiotics, such as prescribing them for viral infections, accelerates resistance and compromises treatment outcomes,” Dr. Anthony cautioned. The proposed legislation aims not only to enforce stricter controls on antibiotic distribution but also to combat the growing menace of counterfeit medicines.
Counterfeit drugs present a dual threat: they jeopardise patient safety by offering ineffective or harmful alternatives and contribute to AMR by promoting inadequate treatment practices. “Counterfeit medications undermine our efforts in patient management and pose serious health risks,” Dr. Anthony affirmed.
Under the new regulations, healthcare providers and drug importers will be required to report adverse drug reactions promptly. This measure aims to enhance post-market surveillance and ensure the continuous monitoring of medication safety and efficacy. Dr. Anthony highlighted the importance of vigilance in monitoring medications, particularly in diverse populations where clinical trials may not fully capture local health dynamics.
“Our goal is to implement stringent treatment guidelines that phase out obsolete medications and guide importers towards safer alternatives,” Dr. Anthony explained. The reforms include elevating our Food and Drug Administration to a Level 3 entity, aligning our regulatory standards with international benchmarks recommended by organisations like the Pan-American Health Organisation (PAHO).
Looking ahead, Dr. Anthony outlined upcoming international initiatives aimed at combating AMR. These efforts include a high-level meeting scheduled for September 2024, where a political declaration is expected to mobilise global commitment and establish an inter-governmental panel dedicated to addressing AMR through evidence-based strategies.
While acknowledging the government’s recent actions as a positive step forward – even though long overdue – stakeholders are urged to uphold the highest standards of patient care and regulatory compliance. The challenges posed by AMR and counterfeit drugs demand concerted efforts from all sectors of the healthcare industry to safeguard public health effectively.
